| abstract |
Materials and methods for treating patients with hemoglobinopathy both ex vivo and in vivo, and deletion, modification or inactivation of the transcriptional regulatory sequence of the BCL11A gene in cells by genomic editing Materials and methods. [Selected figure] Figure 2B |